ICER Publishes Final Evidence Report on Gene Therapies for Sickle Cell Disease
— Despite uncertainty regarding longer-term outcomes, lovo-cel and exa-cel both estimated to produce substantial gains in length and qualit…
Related Articles
AMP® Amyotrophic Lateral Sclerosis (ALS)
AMP ALS, the latest public-private partnership in the FNIH’s growing AMP portfolio, will centralize and build the largest data source for ALS research. This …
AMP Amyotrophic Lateral Sclerosis | FNIH
The Accelerating Medicines Partnership® (AMP®) Amyotrophic Lateral Sclerosis (AMP ALS) is accelerating therapeutic and biomarker development for familial and sporadic ALS by addressing the challenges…
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology
Nature Reviews Neurology – In this Perspective, the authors propose a new classification system for amyotrophic lateral sclerosis and related neurodegenerative disorders that recognizes, in…
We All Need to Get Better at Disagreements
Plan ahead. Actively listen. And discuss how to move forward.
Medical crowdfunding isn’t a solution for skyrocketing health care costs
Nora Kenworthy has spent years studying the world of crowdfunding for health care — along with the way it ends up amplifying the inequities that…
Exclusive | Neuralink Gets FDA Green Light for Second Patient, as First Describes His Emotional Journey
The Elon Musk-backed startup has proposed solutions for a thread pullout problem experienced by its first participant, Noland Arbaugh.
Stakeholders provide feedback on FDA draft guidance on drug development for early Alzheimer’s disease | RAPS
Guidance for developing drugs to treat early Alzheimer@s disease should focus on factors such as cognitive changes and brain atrophy, according to comments submitted to…
Stowers Institute investigator has breakthrough in ALS research
A local man is thankful for the groundbreaking research happening in a lab at the Stowers Institute in Kansas City, Missouri.
Scientists unravel genetic basis for neurodegenerative disorders that
NIH-led findings point to a biomarker for rare disorders associated with the gene PNPLA6.
This woman has ALS. So did 22 of her relatives. What she wants you to know.
A new medication is offering some ALS patients more hope than ever. It’s actually slowing the disease down in some people like Jessica Morris.